• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

62.43 -0.80 (-1.27%)
Delayed Quote Updated: 2:11 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 657,346
Open 62.66
Bid (Size) 62.36 (300)
Ask (Size) 62.47 (100)
Prev. Close 63.23
Today's Range 61.65 - 62.86
52wk Range 61.23 - 90.87
Shares Outstanding 81,474,366
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal ↗
August 16, 2026
PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to... 
Via MarketBeat
Topics Bankruptcy
News headline image
PTC Therapeutics Q2 Earnings Call Highlights ↗
July 31, 2026
PTC Therapeutics (NASDAQ:PTCT) reported second-quarter total revenue of $361 million and raised its 2026 outlook, citing continued growth from its Sephience launch and greater durability than expected... 
Via MarketBeat
Topics Earnings

Performance

52-Week Range 31.3% below 52-week high
62.43
61.2352W Low 90.8752W High
1 Week 4.8% below 1-week high
62.601W Low 65.561W High

PTC Therapeutics, Inc. - Common Stock (PTCT) traded between $61.23 and $90.87 over the past 52 weeks and last traded at $62.43, 31.3% below its 52-week high. Over the past week it ranged between $62.60 and $65.56.

Past 12 Months
-2.7%
-9.3%
-29.5%
-12.4%
-18.6%
-2.3%
1W -$1.70
1M -$6.38
3M -$26.14
6M -$8.83
YTD -$14.31
1Y -$1.48

PTCT was -2.3% over the past year, -12.4% over six months, -18.6% year to date, -2.7% in the last week.

12 Months vs Market
PTCT
-2.3%
DIA
+9.6%
SPY
+15.4%
QQQ
+23.4%
IWM
+13.6%

Over the past 12 months PTCT returned -2.3% versus DIA (Dow) +9.6%, SPY (S&P 500) +15.4%, QQQ (Nasdaq 100) +23.4% and IWM (Russell 2000) +13.6%.

Volume & Liquidity 0.57× 3-mo avg
Today 657,346 3-mo avg 1.1M
1W
1.1M
1M
1.3M
3M
1.1M
6M
1.5M
YTD
1.4M
1Y
1.4M

PTCT most recently traded 657,346 shares against a 3-month average daily volume of 1.1M.

More News

Read More
PTC Therapeutics (NASDAQ:PTCT) Soars on Q2 Earnings Beat and Raised Guidance ↗
July 30, 2026
Via Chartmill
Topics Earnings
News headline image
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million ↗
July 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
PTC THERAPEUTICS INC (NASDAQ:PTCT) Scores Perfect 10/10 For Technical Breakout Setup ↗
June 12, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Delivers Q1 Earnings Beat and Raises 2026 Guidance ↗
May 07, 2026
Via Chartmill
Topics Earnings
PTC Therapeutics Inc (NASDAQ:PTCT) Stock Slides After Q4 Earnings Miss ↗
February 19, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
February 12, 2026
Via Chartmill
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
May 29, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
May 29, 2026
Via The Motley Fool
News headline image
PTC Therapeutics Q1 Earnings Call Highlights ↗
May 08, 2026
Via MarketBeat
Topics Earnings
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation ↗
February 07, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup ↗
February 02, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate ↗
January 12, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup ↗
January 09, 2026
Via Chartmill
News headline image
PTCT Q1 2026 Earnings Transcript ↗
May 08, 2026
Via The Motley Fool
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
March 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
March 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
PTC Therapeutics Inc (NASDAQ:PTCT): A Prime Candidate for Affordable Growth Investing ↗
January 01, 2026
Via Chartmill
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
March 20, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
March 03, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows High-Growth Momentum and Bullish Technical Setup ↗
December 15, 2025
Via Chartmill
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
December 13, 2025
Via Chartmill

Frequently Asked Questions

Is PTC Therapeutics, Inc. - Common Stock publicly traded?
Yes, PTC Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does PTC Therapeutics, Inc. - Common Stock trade on?
PTC Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PTC Therapeutics, Inc. - Common Stock?
The ticker symbol for PTC Therapeutics, Inc. - Common Stock is PTCT on the Nasdaq Stock Market
What is the current price of PTC Therapeutics, Inc. - Common Stock?
The current price of PTC Therapeutics, Inc. - Common Stock is 62.43
When was PTC Therapeutics, Inc. - Common Stock last traded?
The last trade of PTC Therapeutics, Inc. - Common Stock was at 10/08/26 02:11 PM ET
What is the market capitalization of PTC Therapeutics, Inc. - Common Stock?
The market capitalization of PTC Therapeutics, Inc. - Common Stock is 5.09B
How many shares of PTC Therapeutics, Inc. - Common Stock are outstanding?
PTC Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap